Use of meganucleases for inducing homologous recombination...

Details Use of meganucleases for inducing homologous recombination... Use of meganucleases for inducing homologous recombination...

2010-02-23

2010-11-30

Hutson, Richard G (Department: 1652)

Chemistry: molecular biology and microbiology

Enzyme , proenzyme; compositions thereof; process for...

Hydrolase

C435S196000, C435S183000, C435S069700, C530S350000

Reexamination Certificate

active

07842489

ABSTRACT:
A single chain homing endonuclease, comprising a first variant of I-CreI having the amino acid sequence of accession number pdb 1g9y (SEQ ID NO: 23 is residues 1-153 of pdb Ig9y) and a second variant of I-CreI variant having the amino acid sequence of accession number pdb 1g9y (SEQ ID NO: 23 is residues 1-153 of pdb Ig9y) in a single polypeptide.

REFERENCES:
patent: 4179337 (1979-12-01), Davies et al.
patent: 5006333 (1991-04-01), Saifer et al.
patent: 5272071 (1993-12-01), Chappel
patent: 5436150 (1995-07-01), Chandrasegaran
patent: 5474896 (1995-12-01), Dujon et al.
patent: 5641670 (1997-06-01), Treco et al.
patent: 5792632 (1998-08-01), Dujon et al.
patent: 5801030 (1998-09-01), McVey et al.
patent: 5830729 (1998-11-01), Jaisser et al.
patent: 5843701 (1998-12-01), Gold et al.
patent: 5866361 (1999-02-01), Dujon et al.
patent: 5948678 (1999-09-01), Dujon et al.
patent: 5962327 (1999-10-01), Dujon et al.
patent: 6037162 (2000-03-01), Raveh et al.
patent: 6063630 (2000-05-01), Treco et al.
patent: 6232112 (2001-05-01), Catcheside
patent: 6238924 (2001-05-01), Dujon et al.
patent: 6395959 (2002-05-01), Dujon et al.
patent: 6528313 (2003-03-01), Le Mouellic et al.
patent: 6528314 (2003-03-01), Le Mouellic et al.
patent: 6610545 (2003-08-01), Dujon et al.
patent: 7309605 (2007-12-01), Dujon et al.
patent: 7462758 (2008-12-01), Biesgen et al.
patent: 2003/0096249 (2003-05-01), Westphal et al.
patent: 2003/0228583 (2003-12-01), Amacher et al.
patent: 2004/0002092 (2004-01-01), Arnould et al.
patent: 2005/0064474 (2005-03-01), Urnov et al.
patent: 2005/0172365 (2005-08-01), Puchta et al.
patent: 2006/0206949 (2006-09-01), Arnould et al.
patent: 419 621 (1995-12-01), None
patent: WO 91/17271 (1991-11-01), None
patent: WO 91/18980 (1991-12-01), None
patent: WO 91/19818 (1991-12-01), None
patent: WO 93/08278 (1993-04-01), None
patent: WO 94/18313 (1994-08-01), None
patent: WO 95/09233 (1995-04-01), None
patent: WO 96/14408 (1996-05-01), None
patent: WO 00/46385 (2000-08-01), None
patent: WO 00/46386 (2000-08-01), None
patent: WO 00/47775 (2000-08-01), None
patent: WO 01/70946 (2001-09-01), None
patent: WO 02/42497 (2002-05-01), None
patent: 02/099105 (2002-12-01), None
patent: 03/078619 (2003-09-01), None
patent: WO 2004/067736 (2004-08-01), None
Ngo et al. in The Protein Folding Problem and Tertiary Structure Prediction, 1994, Merz et al. (ed.), Birkhauser, Boston, MA, pp. 433 and 492-495.
Epinat, et al., “A novel engineered meganuclease induces homologous recombination in yeast and mammalian cells”, Nucleic Acids Research, vol. 31, No. 11, pp. 2952-2962, 2003.
Seligman, et al., “Mutations altering the cleavage specificity of an homing endonuclease”, Nucleic Acids Research, vol. 30, No. 17, pp. 3870-3879, 2002.
Seligman, et al., “Genetic Analysis of the Chlamydomonas reinhardtii I-Crel Mobile Intron Homing System inEscherichia coli”, Genetics, vol. 147, pp. 1653-1664, 1997.
Jurica, et al., “DNA Recognition and Cleavage by the LAGLIDADG Homing Endonuclease I-Crel” Molecular Cell, vol. 2, pp. 469-476, Oct. 1998.
Lucas, et al., “Rapid evolution of the DNA-binding site in LAGLIDADG Homing Endonucleases”, Nucleic Acids Research, vol. 29, No. 4, pp. 960-969, 2001.
Chevalier, et al., “Design, Activity, and Structure of a Highly Specific Artificial Endonuclease”, Molecular Cell, vol. 10, pp. 895-905, Oct. 2002.
Aiuti et al., “Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning,” Science, 196: 2410-2413 (2002).
Aiuti et al., “Gene Therapy for Immunodeficiency Due to Adenosine Deaminase Deficiency,” The New England Journal of Medicine, vol. 360, No. 5, 447-458 (2009).
Biet et al., Homologous Recombination and Gene Targeting (in French with English abstract), Compes Renducs-Biologics, 326(1): 51-64 (2003).
Cavazzana-Calvo et al., “Gene Therapy of Human Sever Combined Imminodificiency (SCID)-X1 Disease,” Science, 288: 669-672 (2000).
Delacote et al., “Importance of the cell cycle Pphase for the choice of the appropriate DSB repair pathway, for genome stability maintenance”, Cell Cycle, 7:1, 33-38 (2008).
Feigin et al., “Modulation of Metabolic Brain Networks After Subthalamic Gene Therapy for Parkinson's Disease,” PNAS, 104: 1959-19564 (2007).
Fischer et al., “LM02 and Gene Therapy for Severe Combined Immunodificiency,” The New England Journal of Medicine, 2526-2527 (2004).
Gaspar et al., “Gene Therapy of X-Linked Severe Combined Immunodificiency by Use of a Pseudotyped Gammaretroviral Vector,” Lancet, 364: 2181-2187 (2004).
Guo et al., Group II Introns Designed to Insert into Therapeutically Relevant DNA Target Sites in Human Cells, 289: 452-457 (2000).
Hacein-Bey-Abina et al., “LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1,” Science, 415-419 (2003).
Harding et al., “Intravenous Administration of an AAV-2 vector for the expression of factor IX in mice and a dog model of hemophilia B”, Gene Therapy, 11:204-213 (2004).
Jasin, “Genetic Manipulation of genomes with Rare-Cutting Endonucleases,” Trends in Genetics, vol. 12, No. 6, 224-228 (1996).
Kaplitt et al., “Safety and Tolerability of Gene Therapy with an Adeno-Associated Virus (AAV) Borne GAD Gene for Parkinson's Disease: An Open Label, Phase 1 Trial,” Lancet, 369: 2097-2105 (2007).
Kohn et al., “Occurrence of Leukaemia Following Gene Therapy of X-Linked Scid,” Nature Reviews-Cancer, (3):477-488 (2003).
Liu et al., “Naked DNA in Gene Therapy,” Encyclopedia of Life Science, 1-4 (2005).
Logan et al., “Advances in Lentiviral Vector Design for Gene-Modification of Hematopoietic Stem Cells,” Current Opinion in Biotechnology, 13: 429-436 (2002).
Miller et al., “Retroviral Vectors in Gene Therapy”, Encyclopedia of Life Science, 1-5 (2005).
Pfeifer et al., “Transduction of Liver Cells by Lentiviral Vectors: Analysis in Living Animals by Fluorescence Imaging”, Molecular Therapy, vol. 3, No. 3 (2001).
Philpott et al., “Viral Vectors for Gene Therapy,” Encyclopedia of Life Sciences, 1-6 (2007).
Russell, “Replicating Vectors for Gene Therapy of Cancer: Risks, Limitations and prospects,” European Journal Cancer, 30A(8): 1165-117.
Sirven et al., “The Human Immunodeficiency Virus Type-1 Central DNA Flap is a Crucial Determinant of Lentiviral Vector Nuclear Import and Gene Transduction of Human Hematopoietc Stem Cells,” Blood, vol. 96, No. 13, 4103-4110 (2000).
Thomas et al., “Progress and Problems with the Use of Viral Vectors for Gene Therapy,” Nature, vol. 346, No. 4: 335-346 (2003).
Verma et al., “Gene Therapy: Promises, Problems and Prospects,” Nature, vol. 389, 239-242 (1997).
Wilson et al., “Good News on the Clinical Gene Transfer Front,” Human Gene Therapy, 19: 429-430 (2008).
Zennou et al., “HIV-1 Genome Nuclear Import is Mediated by a Central DNA Flap,” Cell, 101: 173-185 (2000).
Zhong et al., “Adeno-Associated viral Vectors in Gene Therapy,” Encyclopedia of Life Sciences, 1-8 (2007).
Wilson, “Pointing Fingers at the Limiting Step in Gene Targeting,” Nature Biotechnology, 21(7): 759-760 (2003).
International Search Report of PCT/IB2004/000848 dated Jul. 23, 2004.
Arimondo et al., “Directing Topoisomerase I Mediated DNA Cleavage to Specific Sites by Camptothecin Tethered to Minor- and Major-Groove Ligands,” Angew Chem Int. Ed Engl, 40:3045-3048 (2001).
Arimondo et al., “Design of New Anti-Cancer Agents Based on Topoisomerase Poisons Targeted to Specific DNA Sequences,” Curr Med. Chem Anti-Canc Agents, 1:219-235 (2001).
Bae et al., “Human Zinc Fingers as Building Blocks in the Construction of Artificial Transcription Factors,” Nat. Biotechnol, 21: 275-280 (2003).
Bell-Pedersen et al., “A Site-

Affiliated with

Also associated with

Rating

Use of meganucleases for inducing homologous recombination... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of meganucleases for inducing homologous recombination..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of meganucleases for inducing homologous recombination... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4160521